Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of
cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are …

Technical advances in genome sequencing and the implementation of next-generation
sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Next-generation sequencing (NGS) may enable more focused and highly personalized
cancer treatment, with the National Comprehensive Cancer Network and European Society …

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing
efforts for its early detection by screening populations at risk, the majority of lung cancer …

Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic
targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and …

Introduction Most published guidelines for genomic biomarker testing in NSCLC reflect the
disease epidemiology and treatments readily available in Europe and North America …

PURPOSE The aim of this study was to assess the cost-effectiveness of using next-
generation sequencing (NGS) versus single-gene testing (SgT) for the detection of genetic …